prikaz prve stranice dokumenta Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra
  Download
PDF 652.05 KB
Scientific paper - Original scientific paper
Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra
Liječnički vjesnik, 142 (2020), 9-10; 306-314. https://doi.org/10.26800/LV-142-9-10-47
Glodić, Goran; Koprivanac, Antun; Mažuranić, Anton; Dujmović, Tomislav; Marušić, Ante; Pleština, Sanja; Kukulj, Suzana; Bitar, Lela; Seiwerth, Fran; Seiwerth, Sven; Brčić, Luka; Stančić Rokotov, Dinko; Janevski, Zoran; Djaković, Željko; Džubur, Feđa; Janković Makek, Mateja; Redžepi, Gzim; Samaržija, Miroslav; Jakopović, Marko More authors...

Cite this document

Glodić, G., Koprivanac, A., Mažuranić, A., Dujmović, T., Marušić, A., Pleština, S. ... Jakopović, M. (2020). Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra. Liječnički vjesnik, 142. (9-10), 306-314. doi: 10.26800/LV-142-9-10-47

Glodić, Goran, et al. "Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra." Liječnički vjesnik, vol. 142, no. 9-10, 2020, pp. 306-314. https://doi.org/10.26800/LV-142-9-10-47

Glodić, Goran, Antun Koprivanac, Anton Mažuranić, Tomislav Dujmović, Ante Marušić, Sanja Pleština, Suzana Kukulj, et al. "Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra." Liječnički vjesnik 142, no. 9-10 (2020): 306-314. https://doi.org/10.26800/LV-142-9-10-47

Glodić, G., et al. (2020) 'Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra', Liječnički vjesnik, 142(9-10), pp. 306-314. doi: 10.26800/LV-142-9-10-47

Glodić G, Koprivanac A, Mažuranić A, Dujmović T, Marušić A, Pleština S, and sur.. Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra. Liječnički vjesnik [Internet]. 2020 [cited 2024 December 21];142(9-10):306-314. doi: 10.26800/LV-142-9-10-47

G. Glodić, et al., "Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra", Liječnički vjesnik, vol. 142, no. 9-10, pp. 306-314, 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:577592. [Accessed: 21 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (croatian)Klinička obilježja i preživljenje bolesnika s malignim mezoteliomom pleure – iskustvo jednog centra
Title (english)Clinical characteristics and survival of patients with malignant pleural mesothelioma: a single center study
AuthorGoran Glodić
AuthorAntun Koprivanac
AuthorAnton Mažuranić
AuthorTomislav Dujmović
AuthorAnte Marušić
AuthorSanja Pleština
AuthorSuzana Kukulj
AuthorLela Bitar
AuthorFran Seiwerth
AuthorSven Seiwerth
AuthorLuka Brčić
AuthorDinko Stančić Rokotov
AuthorZoran Janevski
AuthorŽeljko Djaković
AuthorFeđa Džubur
AuthorMateja Janković Makek
AuthorGzim Redžepi
AuthorMiroslav Samaržija
AuthorMarko Jakopović
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Surgery)
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Pathology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Surgery
Abstract (croatian)
Maligni pleuralni mezoteliom rijetka je i agresivna primarna novotvorina mezotelnih stanica pleure. Glavni rizični čimbenik je izloženost azbestu, najčešće uz latenciju od 30–50 godina. Unatoč terapiji medijan preživljenja je od 4 do 18 mjeseci, ovisno o izvoru. Cilj istraživanja bio je odrediti karakteristike bolesnika oboljelih od malignoga pleuralnog mezotelioma te ishode njihova liječenja na KBC Zagreb u razdoblju od 1999. do 2012. godine. Ispitane su karakteristike 101 bolesnika dijagnosticiranog i liječenog na KBC Zagreb u razdoblju od rujna 1999. do rujna 2012. Analizirali smo ukupno preživljenje (OS), preživljenje bez progresije bolesti (PFS) te preživljenje ovisno o histološkom podtipu tumora, dobi, kliničkom stadiju, pleurodezi talkom i modalitetu liječenja. Koristili smo Kaplan-Meierovu metodu za izradu krivulje preživljenja. 89 bolesnika bilo je muškog, 12 ženskog spola, a medijan dobi 62 godine. Prema TNM klasifikaciji stadij IV je utvrđen kod 69,3%, stadij III kod 26,73%, te stadij II kod samo 3,96% bolesnika. 73,26% bolesnika imalo je epiteloidni, 4,95% sarkomatoidni, 1% mješoviti te 20,79% NOS (nespecifirani) histološki podtip bolesti. Kirurški je liječeno 14,85% bolesnika, kemoterapijom 55,44%, dok je radioterapija primijenjena kod 9,9% bolesnika. Medijan OS iznosi 11 mjeseci, dok je PFS 10 mjeseci. Prema histološkom podtipu medijan OS iznosio je 11 mjeseci za epiteloidni, 12,5 za NOS te 5,5 za sarkomatoidni, a prema kliničkom stadiju 7 mjeseci za stadij II, 17,5 mjeseci za stadij III te 11 mjeseci za stadij IV. Medijan OS bio je dulji u skupini bolesnika mlađoj od 65 godina (12 naspram 8,5 mjeseci, p=0.28), skupini sa učinjenom pleurodezom (13 naspram 7,5 mjeseci, p=0.06) te u skupini liječenoj kemoterapijom (12,5 naspram 7,5 mjeseci, p=0.10). Očekivano preživljenje bolesnika oboljelih od malignoga pleuralnog mezotelioma u Republici Hrvatskoj u skladu je s podatcima iz literature. Ispitane metode liječenja relativno skromno utječu na preživljenje bolesnika.
Abstract (english)
Malignant pleural mesothelioma (MPM) is an aggressive tumor that develops from the mesothelial cells lining the pleural cavity. The most relevant risk factor is asbestos exposure. Despite therapy the median survival is poor ranging from four to 18 months. The aims and objectives of this study were to assess the clinical characteristics and survival of patients with MPM treated at UHC Zagreb. This study included 101 patients diagnosed and treated for MPM at UHC Zagreb from September 1999 to September 2012. We analyzed the overall survival (OS), progression free survival (PFS) and OS depending on histological subtype, clinical stage, age, treatment method and pleurodesis performed using the Kaplan-Meier method. Eighty-nine patients were male and 12 female with the median age of 62 years. Using the TNM staging system, 69.3% were stage IV, 26.73% were stage III and 3.96% were stage II. 73.26% of MPM were epitheloid, 4.95% sarcomatous and 20.79% were NOS (non otherwise specified) histological subtype. 14.85% of patients had surgery, 55.44% of patients received chemotherapy and 9.9% radiotherapy. Median OS was 11 months and PFS was ten months. OS by histological subtype was 11 months for epitheloid, 12.5 months for NOS and 5.5 months for sarcomatous MPM. OS by TNM stage was seven months for stage II, 17.5 months for stage III and 11 months for stage IV disease. Median OS was longer for patients younger than 65 (12 vs. 8.5 months, p=0.28), patients treated with pleurodesis (13 vs. 7.5 months, p=0.06) and patients who received chemotherapy (12.5 vs. 7.5 months, p=0.10). The overall survival and prognosis of patients with malignant pleural mesothelioma in Croatia is poor in accordance with the literature. The studied treatment methods offer only a modest survival benefit to our patients.
Keywords (croatian)
Keywords (english)
Languagecroatian
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleLiječnički vjesnik
Numberingvol. 142, no. 9-10, pp. 306-314
p-ISSN0024-3477
e-ISSN1849-2177
DOIhttps://doi.org/10.26800/LV-142-9-10-47
URN:NBNurn:nbn:hr:105:577592
Publication2020
Document URLhttps://hrcak.srce.hr/245806
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2020-12-04 13:06:42